In collaboration with FENS and Wiley-Blackwell, EJN is proud to announce the winner of the Best Publication Award 2013:
Combined delivery of Nogo-A antibody, Neurotrophin-3 and NMDA-NR2D subunits establishes a functional detour in the hemisected spinal cord by Lisa Schnell, Arsen S. Hunanyan William J. Bowers, Philip J. Horner, Howard J. Federoff, Miriam Gullo, Martin E. Schwab, Lorne M. Mendell and Victor L. Arvanian, published in Volume 34, Issue 8, pages 1256–1267, October 2011
Dr. Lisa Schnell, researcher at the Brain Research Institute of the University and ETH of Zurich, Zurich, Switzerland, is first author of this research report that has been awarded the 2013 EJN best Publication Award.
Dr. Schnell received this award of £3,000 at the FENS Featured Regional Meeting in Prague, September 11-14, 2013. She gave a Special Lecture at this meeting.
The main focus of Dr. Schnell’s work is to understand the complex neuronal and molecular events that follow injury of the spinal cord. Despite early regenerative processes, functional healing of the damaged tissue does not occur. The discovery of the growth-inhibitory myelin component Nogo-A in the laboratory of Dr. Martin E. Schwab, and its subsequent neutralization with an antibody in vivo, has been a major turning point in the field of spinal cord injury. Their demonstration of long-distance regeneration of axons has had a tremendous impact on the scientific community and drew many researchers into this fascinating area. In the EJN research report that was selected as the winner of the Best Publication Award 2013, the authors have conducted anatomical tracing, electrophysiology and behavioral experiments and found that, in adult rats, the combined treatment of anti-Nogo-A antibody, neurotrophin NT-3 and NR2d subunits of NMDA receptors induced the appearance of a functional “detour” around the lesion and improved recovery of function after spinal cord injury in adult rats. This novel combination treatment holds great promise to help improve the function of the damaged spinal cord.
Dr. Schnell’s research for the benefit of paraplegic patients was supported by the Christopher and Dana Reeve Foundation.